Francois Durand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2565576/publications.pdf

Version: 2024-02-01

252 papers

23,854 citations

70 h-index

11651

148 g-index

259 all docs

259 docs citations

times ranked

259

17135 citing authors

#	Article	IF	CITATIONS
1	Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. Journal of Hepatology, 2022, 76, 115-122.	3.7	6
2	Contrastâ€enhanced CT and liver surface nodularity for the diagnosis of portoâ€sinusoidal vascular disorder: A caseâ€control study. Hepatology, 2022, 76, 418-428.	7.3	11
3	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. American Journal of Hematology, 2022, 97, 431-439.	4.1	7
4	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. JHEP Reports, 2022, 4, 100445.	4.9	6
5	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatology Communications, 2022, 6, 1100-1112.	4.3	5
6	Laparoscopic assisted liver transplantation: A realistic perspective. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S78-S78.	0.1	0
7	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339.	3.7	76
8	Liver Stiffness by Transient Elastography to Detect Portoâ€Sinusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74, 364-378.	7.3	40
9	Hepatorenal Syndrome. Critical Care Clinics, 2021, 37, 321-334.	2.6	6
10	Liver Transplantation in the Setting of Non-malignant Portal Vein Thrombosis., 2021, , 131-156.		0
10	Liver Transplantation in the Setting of Non-malignant Portal Vein Thrombosis. , 2021, , 131-156. Acuteâ€onâ€chronic liver failure: Where do we stand?. Liver International, 2021, 41, 128-136.	3.9	8
		3.9 7. 3	
11	Acuteâ€onâ€chronic liver failure: Where do we stand?. Liver International, 2021, 41, 128-136.		8
11 12	Acuteâ€onâ€chronic liver failure: Where do we stand?. Liver International, 2021, 41, 128-136. The Use of Rifaximin in Patients With Cirrhosis. Hepatology, 2021, 74, 1660-1673. Covid-19 in liver transplant recipients: the French SOT COVID registry. Clinics and Research in	7.3	67
11 12 13	Acuteâ€onâ€chronic liver failure: Where do we stand?. Liver International, 2021, 41, 128-136. The Use of Rifaximin in Patients With Cirrhosis. Hepatology, 2021, 74, 1660-1673. Covid-19 in liver transplant recipients: the French SOT COVID registry. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101639. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusâ€related infection before and after liver	7.3 1.5	8 67 40
11 12 13	Acuteâ€onâ€chronic liver failure: Where do we stand?. Liver International, 2021, 41, 128-136. The Use of Rifaximin in Patients With Cirrhosis. Hepatology, 2021, 74, 1660-1673. Covid-19 in liver transplant recipients: the French SOT COVID registry. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101639. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusâ€related infection before and after liver transplantation. Alimentary Pharmacology and Therapeutics, 2021, 54, 583-605. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004	7.3 1.5 3.7	8 67 40 27
11 12 13 14	Acuteâ€onâ€chronic liver failure: Where do we stand?. Liver International, 2021, 41, 128-136. The Use of Rifaximin in Patients With Cirrhosis. Hepatology, 2021, 74, 1660-1673. Covid-19 in liver transplant recipients: the French SOT COVID registry. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101639. 2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virusâ€related infection before and after liver transplantation. Alimentary Pharmacology and Therapeutics, 2021, 54, 583-605. Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101514. Estimating Glomerular Filtration Rate in Cirrhosis Using Creatinineâ€Based and Cystatin C–Based	7.3 1.5 3.7	8 67 40 27

#	Article	IF	CITATIONS
19	Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. Journal of Hepatology, 2020, 72, 463-471.	3.7	38
20	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2020, 5, 31-41.	8.1	75
21	Efficacy of Albumin Treatment for Patients with CirrhosisÂandÂlnfections Unrelated to Spontaneous BacterialÂPeritonitis. Clinical Gastroenterology and Hepatology, 2020, 18, 963-973.e14.	4.4	77
22	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. Journal of Hepatology, 2020, 72, 688-701.	3.7	223
23	Optimizing Allocation of Older Donors in Liver Transplantation: The Objectives of Allocation Policies Also Matter. Transplantation, 2020, 104, 673-674.	1.0	1
24	Laparoscopic Liver Transplantation. Annals of Surgery, 2020, 272, 889-893.	4.2	16
25	Use of Artificial Intelligence as an Innovative Method for Liver Graft Macrosteatosis Assessment. Liver Transplantation, 2020, 26, 1224-1232.	2.4	21
26	Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139.	3.7	78
27	Liver transplantation for critically ill cirrhotic patients: Stratifying utility based on pretransplant factors. American Journal of Transplantation, 2020, 20, 2437-2448.	4.7	83
28	Development and outcomes of the French liver allocation system. Current Opinion in Organ Transplantation, 2020, 25, 132-138.	1.6	5
29	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Frontiers in Immunology, 2020, 11, 619039.	4.8	39
30	Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	2
31	Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation, 2020, 104, 1136-1142.	1.0	105
32	Renal Dysfunction in Patients with Cirrhosis. , 2020, , 67-90.		0
33	Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. European Journal of Clinical Pharmacology, 2019, 75, 1555-1563.	1.9	0
34	Early N-acetylcysteine for hospitalised patients with yellow fever. Lancet Infectious Diseases, The, 2019, 19, 1055.	9.1	0
35	Liver Transplantation in France. Liver Transplantation, 2019, 25, 763-770.	2.4	33
36	Liver transplantation for non-alcoholic steatohepatitis in Europe: Where do we stand?. Journal of Hepatology, 2019, 71, 240-242.	3.7	7

#	Article	IF	CITATIONS
37	Amatoxin poisoning: Immediate transfer to intensive care or liver unit of patients at early risk of severe acute liver injury. Liver International, 2019, 39, 1016-1018.	3.9	2
38	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology, 2019, 157, 149-162.	1.3	178
39	Impact of the new MELDâ€based allocation system on waiting list and postâ€transplant survival—a cohort analysis using the French national <scp>CRISTAL</scp> database. Transplant International, 2019, 32, 1061-1073.	1.6	13
40	Hepatorenal Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 774-781.	4.5	80
41	Modified Technique of Total Hepatectomy in Polycystic Liver Disease With Caval Flow Preservation: The Exposure Left Lateral Sectionectomy. Transplantation, 2019, 103, 1414-1417.	1.0	7
42	Short―and Longâ€Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. World Journal of Surgery, 2019, 43, 2048-2060.	1.6	17
43	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	1.3	296
44	Acute kidney injury in cirrhosis: implications for liver transplantation. Current Opinion in Critical Care, 2019, 25, 171-178.	3.2	19
45	Further to the Right: Piggyback Anastomosis on the Right Hepatic Vein Facilitates the Implantation of Small Liver Grafts (the One-vein Technique). Annals of Surgery, 2019, 269, e60-e62.	4.2	4
46	Age and liver transplantation. Journal of Hepatology, 2019, 70, 745-758.	3.7	186
47	Endovascular Treatment of Arterial Complications After Liver Transplantation: Long-Term Follow-Up Evaluated on Doppler Ultrasound and Magnetic Resonance Cholangiopancreatography. CardioVascular and Interventional Radiology, 2019, 42, 381-388.	2.0	11
48	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. Journal of Hepatology, 2019, 70, 398-411.	3.7	225
49	Acute Kidney Injury in Cirrhosis. , 2019, , 263-271.e3.		0
50	Orchestration of Tryptophanâ€Kynurenine Pathway, Acute Decompensation, and Acuteâ€onâ€Chronic Liver Failure in Cirrhosis. Hepatology, 2019, 69, 1686-1701.	7.3	80
51	Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Digestive and Liver Disease, 2018, 50, 668-674.	0.9	24
52	How to improve longâ€ŧerm outcome after liver transplantation?. Liver International, 2018, 38, 134-138.	3.9	53
53	Noninvasive assessment of liver steatosis in deceased donors: A pilot study. Liver Transplantation, 2018, 24, 551-556.	2.4	7
54	Renal Complications in Acute and Chronic Liver Disease. , 2018, , 153-161.		0

#	Article	lF	Citations
55	Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis. Hepatology, 2018, 68, 1508-1518.	7.3	33
56	Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation. Transplantation, 2018, 102, 119-126.	1.0	18
57	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Radiology, 2018, 289, 698-707.	7.3	45
58	Acute Kidney Injury After Liver Transplantation. Transplantation, 2018, 102, 1636-1649.	1.0	89
59	Muscle mass vs. adipose tissue to predict outcome in cirrhosis: Which matters and in which patients?. Journal of Hepatology, 2018, 69, 567-569.	3.7	7
60	Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients. Liver Transplantation, 2018, 24, 1425-1436.	2.4	44
61	An outbreak of <i>Pneumocytis jirovecii</i> pneumonia among liver transplant recipients. Transplant Infectious Disease, 2018, 20, e12956.	1.7	11
62	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. Journal of Hepatology, 2017, 66, 930-941.	3.7	26
63	The future of liver transplantation for viral hepatitis. Liver International, 2017, 37, 130-135.	3.9	19
64	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology, 2017, 66, 555-563.	7.3	91
65	Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explantâ€based prognostic models. Liver International, 2017, 37, 717-726.	3.9	21
66	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	3.7	50
67	The International Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline. Transplantation, 2017, 101, 938-944.	1.0	93
68	Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms. Transplantation, 2017, 101, 1830-1837.	1.0	32
69	Estimation of the prevalence of intraductal papillary mucinous neoplasm of the pancreas in the French population through patients waiting for liver transplantation. United European Gastroenterology Journal, 2017, 5, 499-503.	3.8	30
70	A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis. Clinical Cancer Research, 2017, 23, 2750-2758.	7.0	31
71	Longâ€ŧerm outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	7.3	68
72	Renal dysfunction and cirrhosis. Current Opinion in Critical Care, 2017, 23, 457-462.	3.2	11

#	Article	IF	Citations
73	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 56-65.	1.5	0
74	Liver sinusoidal endothelial cells: Physiology and role in liver diseases. Journal of Hepatology, 2017, 66, 212-227.	3.7	639
75	Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Critical Care, 2017, 21, 321.	5.8	19
76	Development of an organ failure score in acute liver failure for transplant selection and identification of patients at high risk of futility. PLoS ONE, 2017, 12, e0188151.	2.5	16
77	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Annals of Hepatology, 2017, 16, 375-381.	1.5	1
78	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World Journal of Gastroenterology, 2016, 22, 4547.	3.3	12
79	A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases. PLoS ONE, 2016, 11, e0150733.	2.5	8
80	The International Liver Transplant Society Guideline on Living Liver Donation. Transplantation, 2016, 100, 1238-1243.	1.0	61
81	Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus. Transplantation, 2016, 100, 1705-1713.	1.0	14
82	Kidney biomarkers in cirrhosis. Journal of Hepatology, 2016, 65, 809-824.	3.7	116
83	Use of everolimus in liver transplantation: The French experience. Transplantation Reviews, 2016, 30, 161-170.	2.9	19
84	Management of Acute-on-Chronic Liver Failure. Seminars in Liver Disease, 2016, 36, 141-152.	3.6	13
85	Systemic inflammation in decompensated cirrhosis: Characterization and role in acuteâ€onâ€chronic liver failure. Hepatology, 2016, 64, 1249-1264.	7.3	550
86	Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transplantation, 2016, 22, 1491-1500.	2.4	31
87	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 914-920.	3.7	35
88	Liver Transplantation With Older Donors. Transplantation, 2016, 100, 2410-2415.	1.0	20
89	Liver transplantation for hepatocellular carcinoma: is zero recurrence theoretically possible?. Hepatobiliary and Pancreatic Diseases International, 2016, 15, 147-151.	1.3	4
90	When Should We Propose Liver Transplant After Resection of Hepatocellular Carcinoma? A Comparison of Salvage and De Principe Strategies. Journal of Gastrointestinal Surgery, 2016, 20, 66-76.	1.7	28

#	Article	IF	CITATIONS
91	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. Journal of Hepatology, 2016, 64, 717-735.	3.7	243
92	Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. American Journal of Kidney Diseases, 2016, 67, 318-328.	1.9	74
93	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut, 2016, 65, 1882-1894.	12.1	140
94	Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia. Medicine (United) Tj ETQq0 0 (0 rgBT /Ov	erlock 10 Tf 5 14
95	Clinical Course of acuteâ€onâ€chronic liver failure syndrome and effects on prognosis. Hepatology, 2015, 62, 243-252.	7.3	493
96	Follow-up Imaging After Liver Transplantation Should Take Into Consideration Primary Hepatocellular Carcinoma Characteristics. Transplantation, 2015, 99, 1613-1618.	1.0	16
97	Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?. PLoS ONE, 2015, 10, e0138091.	2.5	38
98	Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clinical Gastroenterology and Hepatology, 2015, 13, 1993-2001.e2.	4.4	118
99	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut, 2015, 64, 531-537.	12.1	405
100	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology, 2015, 62, 968-974.	3.7	571
101	Interactions between virus-related factors and post-transplant ascites in patients with hepatitis C and no cirrhosis: role of cryoglobulinemia. Transplant International, 2015, 28, 162-169.	1.6	4
102	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. Journal of Hepatology, 2015, 62, 831-840.	3.7	289
103	Acute Kidney Injury in Cirrhosis. Critical Care Clinics, 2015, 31, 737-750.	2.6	27
104	Pregnancy and Vascular Liver Disease. Journal of Clinical and Experimental Hepatology, 2015, 5, 41-50.	0.9	42
105	Massive biliary necrosis as a complication of a hereditary hemorrhagic telangiectasia. European Journal of Gastroenterology and Hepatology, 2015, 27, 471-474.	1.6	4
106	Interplay of Inflammation and Endothelial Dysfunction in Bone Marrow Transplantation: Focus on Hepatic Veno-Occlusive Disease. Seminars in Thrombosis and Hemostasis, 2015, 41, 629-643.	2.7	48
107	The recipient celiac trunk as an alternative to the native hepatic artery for arterial reconstruction in adult liver transplantation. Liver Transplantation, 2015, 21, 1133-1141.	2.4	13
108	Corrigendum to "Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites―[J Hepatol 2015;62:968–974]. Journal of Hepatology, 2015, 63, 290.	3.7	9

#	Article	IF	CITATIONS
109	Assessment of adrenal function in patients with acute hepatitis using serum free and total cortisol. Digestive and Liver Disease, 2015, 47, 783-789.	0.9	7
110	Prospective Comparison of Spleen and Liver Stiffness by Using Shear-Wave and Transient Elastography for Detection of Portal Hypertension in Cirrhosis. Radiology, 2015, 275, 589-598.	7.3	190
111	Liver Autophagy in Anorexia Nervosa and Acute Liver Injury. BioMed Research International, 2014, 2014, 1-10.	1.9	44
112	Complete spontaneous liver graft disappearance after auxiliary liver transplantation. Hepatology, 2014, 60, 1104-1106.	7.3	7
113	Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: Validation of current recommendations. Hepatology, 2014, 59, 1514-1521.	7.3	106
114	Preoperative tumour biopsy does not affect the oncologic course of patients with transplantable HCC. Journal of Hepatology, 2014, 61, 589-593.	3.7	28
115	Is It Worth Discussing the Feasibility of Deceased Donor Liver Transplantation in Centers with a Strong Experience in Living Donor Liver Transplantation?. World Journal of Surgery, 2014, 38, 1529-1530.	1.6	0
116	Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach. AAPS Journal, 2014, 16, 379-391.	4.4	37
117	Long term results of liver transplantation for Wilson's disease: Experience in France. Journal of Hepatology, 2014, 60, 579-589.	3.7	103
118	Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 570-576.	1.5	38
119	Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology, 2014, 60, 823-831.	7.3	135
120	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Journal of Hepatology, 2014, 61, 1038-1047.	3.7	741
121	Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: A French experience on 250 patients over 15Âyears (the OrfÃ'vre study). Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 292-299.	1.5	5
122	Type-1 hepatorenal syndrome in patients with cirrhosis and infection vs. sepsis-induced acute kidney injury: What matters?. Journal of Hepatology, 2014, 60, 907-909.	3.7	10
123	Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. Journal of Hepatology, 2014, 60, 1151-1157.	3.7	304
124	Preservation of the arterial vascularisation after hepatic artery pseudoaneurysm following orthotopic liver transplantation: long-term results. Annals of Transplantation, 2014, 19, 346-352.	0.9	39
125	Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transplantation, 2013, 19, 887-895.	2.4	45
126	The use of a liver with a gunshot injury as a donor for auxiliary liver transplantation: Case report. International Journal of Surgery Case Reports, 2013, 4, 917-919.	0.6	0

#	Article	IF	Citations
127	The role of biopsy of the nontumorous liver parenchyma in patients considered for partial resection of small hepatocellular carcinoma. Hepatology, 2013, 58, 452-452.	7.3	1
128	Intestinal failure after bariatric surgery. Lancet, The, 2013, 382, 742.	13.7	11
129	Albumin Dialysis With a Noncell Artificial Liver Support Device in Patients With Acute Liver Failure. Annals of Internal Medicine, 2013, 159, 522.	3.9	231
130	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	1.3	2,211
131	Mushroom Poisoning. , 2013, , 621-629.		3
132	Repeat endovascular treatment of recurring hepatic artery stenoses in orthotopic liver transplantation. Transplant International, 2013, 26, 608-615.	1.6	35
133	Portomesenteric Shunt for Liver Transplantation and Complete Portal Vein Thrombosis. Transplantation, 2013, 96, e68-e69.	1.0	5
134	Plasma Fibroblast Growth Factor 23 Concentration Is Increased and Predicts Mortality in Patients on the Liver-Transplant Waiting List. PLoS ONE, 2013, 8, e66182.	2.5	57
135	Recurrence after liver transplantation for hepatocellular carcinoma according to up-to-seven criteria. Hepato-Gastroenterology, 2013, 60, 799-806.	0.5	3
136	Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases: Figure 1. Gut, 2012, 61, 1098-1100.	12.1	3
137	"Inherent Limitations―in Donors. Annals of Surgery, 2012, 255, 528-533.	4.2	23
138	Management of critically-ill cirrhotic patients. Journal of Hepatology, 2012, 56, S13-S24.	3.7	113
139	A new look at renal dysfunction in the cirrhotic patient. Critical Care, 2012, 16, 118.	5.8	6
140	Portal vein thrombosis, cirrhosis, and liver transplantation. Journal of Hepatology, 2012, 57, 203-212.	3.7	216
141	Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. Journal of Hepatology, 2012, 57, 274-280.	3.7	67
142	Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin. Journal of Hepatology, 2012, 57, 564-571.	3.7	27
143	Reply to: "Encephalopathy or hepatic encephalopathy?― Journal of Hepatology, 2012, 57, 929-930.	3.7	0
144	Determinants of Recovery from Severe Posterior Reversible Encephalopathy Syndrome. PLoS ONE, 2012, 7, e44534.	2.5	152

#	Article	IF	Citations
145	Pretransplant Fecal Carriage of Extended-Spectrum β-Lactamase–producing∢i>Enterobacteriaceae∢ i>and Infection after Liver Transplant, France. Emerging Infectious Diseases, 2012, 18, 908-916.	4.3	87
146	Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention-to-treat analysis. Hepatology, 2012, 55, 132-140.	7.3	235
147	Extracorporeal membrane oxygenation as a bridge to liver transplantation for acute respiratory distress syndrome-induced life-threatening hypoxaemia aggravated by hepatopulmonary syndrome. Critical Care, 2011, 15, R234.	5.8	47
148	Early Liver Transplantation for Severe Alcoholic Hepatitis. New England Journal of Medicine, 2011, 365, 1790-1800.	27.0	792
149	Obliterative portal venopathy: Portal hypertension is not always present at diagnosis. Journal of Hepatology, 2011, 54, 455-461.	3.7	142
150	The quest for equity in liver transplantation: Another lesson learned from women. Journal of Hepatology, 2011, 54, 401-402.	3.7	3
151	Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. Journal of Hepatology, 2011, 55, 794-799.	3.7	177
152	Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome?. Liver International, 2011, 31, 161-163.	3.9	13
153	Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver International, 2011, 31, 792-801.	3.9	42
154	Detection of bacterial DNA in serum and ascitic fluid of asymptomatic outpatients with cirrhosis and non-neutrocytic ascites. Liver International, 2011, 31, 494-498.	3.9	11
155	Model for end-stage liver disease exceptions in the context of the french model for end-stage liver disease score-based liver allocation system. Liver Transplantation, 2011, 17, 1137-1151.	2.4	68
156	Is tumor biopsy necessary?. Liver Transplantation, 2011, 17, S14-S25.	2.4	38
157	Hot-topic debate on kidney function: Renal-sparing approaches are beneficial. Liver Transplantation, 2011, 17, S43-S49.	2.4	8
158	Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89–IgA and IgG–IgA complexes: common mechanisms for distinct diseases. Kidney International, 2011, 80, 1352-1363.	5.2	69
159	Extended Liver Resection for Polycystic Liver Disease Can Challenge Liver Transplantation. Annals of Surgery, 2010, 252, 735-743.	4.2	55
160	The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. European Journal of Gastroenterology and Hepatology, 2010, 22, 207-212.	1.6	37
161	Acute Liver Disease. Medical Radiology, 2010, , 83-92.	0.1	0
162	Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology, 2010, 52, 1017-1022.	7.3	452

#	Article	IF	Citations
163	Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes. Liver Transplantation, 2010, 16, 393-401.	2.4	101
164	Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: Impact on the model for end-stage liver disease score. Liver Transplantation, 2010, 16, 1169-1177.	2.4	154
165	Renal insufficiency: Management prior to transplantation. Liver Transplantation, 2010, 16, S72-S76.	2.4	5
166	The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver International, 2010, 30, 725-732.	3.9	149
167	The evaluation of renal function and disease in patients with cirrhosis. Journal of Hepatology, 2010, 52, 605-613.	3.7	218
168	Autophagy in liver diseases. Journal of Hepatology, 2010, 53, 1123-1134.	3.7	351
169	Severe sepsis in cirrhosis. Hepatology, 2009, 50, 2022-2033.	7.3	374
170	Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transplantation, 2009, 15, 136-147.	2.4	36
171	Emergency transplantation for acute reactivation of chronic hepatitis B with high viral load: role of antiviral therapy. Liver International, 2009, 29, 775-776.	3.9	0
172	Liver Transplantation for Budd-Chiari Syndrome. , 2009, , 987-994.		0
173	Early prediction of encephalopathy in hospitalized patients with severe acute liver disease: The narrow window of opportunity for transplant-free survival. Journal of Hepatology, 2009, 51, 977-980.	3.7	9
174	Levels and Initial Course of Serum Alanine Aminotransferase Can Predict Outcome of Patients With Budd–Chiari Syndrome. Clinical Gastroenterology and Hepatology, 2009, 7, 1230-1235.	4.4	39
175	Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transplantation, 2008, 14, 1694-1707.	2.4	257
176	Hepatitis E-associated acute liver failure in pregnancy: An Indian puzzle. Hepatology, 2008, 48, 1380-1382.	7.3	16
177	Risk factors for <i>Enterobacteriaceae</i> bacteremia after liver transplantation. Transplant International, 2008, 21, 755-763.	1.6	43
178	Acute Liver Cell Damage in Patients With Anorexia Nervosa: A Possible Role of Starvation-Induced Hepatocyte Autophagy. Gastroenterology, 2008, 135, 840-848.e3.	1.3	165
179	Assessment of Prognosis of Cirrhosis. Seminars in Liver Disease, 2008, 28, 110-122.	3.6	271
180	Herbal medicines in acute viral hepatitis: a ticket for more trouble. European Journal of Gastroenterology and Hepatology, 2008, 20, 161-163.	1.6	12

#	Article	IF	Citations
181	Acute Hypoxic Hepatitis and Hepatic Consequences of Acute Heart Failure Syndrome., 2008,, 763-767.		О
182	Wilson??s disease: an old disease keeps its old secrets. European Journal of Gastroenterology and Hepatology, 2007, 19, 97-99.	1.6	8
183	Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Helical CT and MR Imaging Findings with Clinical-Pathologic Comparison. Radiology, 2007, 243, 422-430.	7. 3	70
184	Amanita phalloides poisoning: Reassessment of prognostic factors and indications for emergency liver transplantation. Journal of Hepatology, 2007, 46, 466-473.	3.7	176
185	Reply to "Reassessment of predictors of fatal outcome in amatoxin poisoning: Some critical comments― Journal of Hepatology, 2007, 47, 425-426.	3.7	3
186	Hepatectomy vs. liver transplantation: A combination rather than an opposition. Liver Transplantation, 2007, 13, 636-638.	2.4	11
187	Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: A case-control study. Liver Transplantation, 2007, 13, 665-671.	2.4	30
188	Liver transplantation for hepatocellular carcinoma: Role of biopsy. Liver Transplantation, 2007, 13, S17-S23.	2.4	40
189	Indications of liver transplantation in patients with complications of cirrhosis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 175-190.	2.4	22
190	Risk scores in cirrhotic patients: From non-transplant surgery to transplantation and back. Journal of Hepatology, 2006, 44, 620-621.	3.7	3
191	Respiratory Complications: A Major Concern after Right Hepatectomy in Living Liver Donors. Transplantation, 2006, 81, 181-186.	1.0	45
192	Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid:. Liver International, 2006, 26, 46-54.	3.9	88
193	A prospective analysis of living-liver donation shows a high rate of adverse events. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 117-122.	2.0	30
194	Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology, 2006, 44, 1308-1316.	7. 3	258
195	Living donor liver transplantation in high-risk vs. low-risk patients: Optimization using statistical models. Liver Transplantation, 2006, 12, 231-239.	2.4	14
196	Impact of UCSF criteria according to pre- and post-OLT tumor features: Analysis of 479 patients listed for HCC with a short waiting time. Liver Transplantation, 2006, 12, 1761-1769.	2.4	405
197	Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Before Liver Transplantation: A Prospective Study with Histopathologic Comparison. American Journal of Roentgenology, 2006, 186, S296-S305.	2.2	68
198	Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients. World Journal of Gastroenterology, 2006, 12, 7319.	3.3	70

#	Article	IF	CITATIONS
199	The ???50-50 Criteria??? on Postoperative Day 5. Annals of Surgery, 2005, 242, 824-829.	4.2	878
200	Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transplantation, 2005, 11, 767-775.	2.4	216
201	Risk factors forStaphylococcus aureus infection in liver transplant recipients. Liver Transplantation, 2005, 11, 1093-1099.	2.4	72
202	Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. Journal of Hepatology, 2005, 42, S100-S107.	3.7	481
203	Indication of liver transplantation following amatoxin intoxication: A word of caution. Journal of Hepatology, 2005, 43, 184-185.	3.7	7
204	Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver International, 2004, 24, 457-464.	3.9	117
205	Harvesting the middle hepatic vein with a right hepatectomy does not increase the risk for the donor. Liver Transplantation, 2004, 10, 71-76.	2.4	61
206	Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transplantation, 2004, 10, S69-S73.	2.4	191
207	Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transplantation, 2004, 10, S86-S90.	2.4	64
208	Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: Results of a multicenter study. Journal of Surgical Oncology, 2004, 85, 36-41.	1.7	119
209	Évaluation de l'état nutritionnel au cours de la cirrhoseÂ: méthodes, limites et implications. Nutrition Clinique Et Metabolisme, 2004, 18, 120-126.	0.5	1
210	ROLE OF REPLICATIVE SENESCENCE IN THE PROGRESSION OF FIBROSIS IN HEPATITIS C VIRUS (HCV) RECURRENCE AFTER LIVER TRANSPLANTATION. Transplantation, 2004, 77, 1755-1760.	1.0	24
211	Multifactorial aetiology of hepatic infarction. European Journal of Gastroenterology and Hepatology, 2004, 16, 411-415.	1.6	24
212	Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology, 2003, 37, 401-409.	7.3	287
213	Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: A study in 17 explanted livers. Hepatology, 2003, 37, 510-519.	7.3	192
214	Liver transplantation for hepatocellular carcinoma: Should we push the limits?. Liver Transplantation, 2003, 9, 697-699.	2.4	25
215	Coagulation disorders in patients with cirrhosis and severe sepsis. Liver International, 2003, 23, 440-448.	3.9	111
216	Prevalence, Molecular Epidemiology, and Clinical Significance of Heterogeneous Glycopeptide-Intermediate <i>Staphylococcus aureus</i> in Liver Transplant Recipients. Journal of Clinical Microbiology, 2003, 41, 5147-5152.	3.9	43

#	Article	IF	Citations
217	Liver transplantation for hepatopulmonary syndrome: A ten-year experience in Paris, France. Transplantation, 2003, 75, 1482-1489.	1.0	150
218	Resection Prior to Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgery, 2003, 238, 885-893.	4.2	381
219	Acute liver failure and bioartificial liver support: preventing the former to obviate the latter. Transplantation, 2003, 75, 1770-1771.	1.0	0
220	Feasibility and Effectiveness of Using Coronary Stents in the Treatment of Hepatic Artery Stenoses After Orthotopic Liver Transplantation. American Journal of Roentgenology, 2002, 178, 1175-1179.	2.2	61
221	Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter study. Gastroenterology, 2002, 122, 923-930.	1.3	429
222	Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 882-888.	2.8	134
223	Pulmonary hemodynamics and gas exchange after liver transplantation in patients with cirrhosis. Digestive Diseases and Sciences, 2002, 47, 746-749.	2.3	8
224	Donor safety in living related liver transplantation: Underestimation of the risks for deep vein thrombosis and pulmonary embolism. Liver Transplantation, 2002, 8, 118-120.	2.4	43
225	Auxiliary liver transplantation for fulminant hepatitis B: Results from a series of six patients with special emphasis on regeneration and recurrence of hepatitis B. Liver Transplantation, 2002, 8, 701-707.	2.4	30
226	Liver transplantation for hepatocellular carcinoma. Hepato-Gastroenterology, 2002, 49, 47-52.	0.5	13
227	Hepatitis after intravenous buprenorphine misuse in heroin addicts. Journal of Hepatology, 2001, 34, 346-350.	3.7	86
228	Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. Journal of Hepatology, 2001, 34, 537-547.	3.7	49
229	Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. Journal of Hepatology, 2001, 35, 254-258.	3.7	236
230	Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis. New England Journal of Medicine, 2001, 344, 23-28.	27.0	218
231	Feasibility and limits of caval-flow preservation during liver transplantation. Liver Transplantation, 2001, 7, 983-987.	2.4	52
232	Vanishing Graft Syndrome After Auxiliary Liver Transplantation. Journal of Hepatology, 2000, 33, 513.	3.7	4
233	Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases. Journal of Hepatology, 2000, 32, 521-527.	3.7	60
234	Pulmonary hypertension following hepatopulmonary syndrome in a patient with cirrhosis. Journal of Hepatology, 1999, 31, 360-364.	3.7	37

#	Article	IF	Citations
235	Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology, 1998, 29, 565-570.	3.7	198
236	Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. Journal of Hepatology, 1997, 26, 722-726.	3.7	25
237	Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. Journal of Hepatology, 1997, 26, 1229-1234.	3.7	51
238	Hepatorenal syndrome. Digestive Diseases and Sciences, 1996, 41, 1054-1056.	2.3	69
239	Hemodynamics after orthotopic liver transplantation: Study of associated factors and long-term effects. Hepatology, 1995, 22, 458-465.	7.3	68
240	Immunostaining for membrane attack complex of complement is related to cell necrosis in fulminant and acute hepatitis. Gastroenterology, 1995, 108, 495-504.	1.3	22
241	Ischemic hepatitis due to obstructive sleep apnea. Gastroenterology, 1995, 109, 1682-1684.	1.3	68
242	Preservation of renal perfusion and postoperative renal function by side-to-side cavo-caval anastomosis in liver transplant recipients. Transplant International, 1995, 8, 407-410.	1.6	7
243	Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology, 1995, 21, 929-932.	7.3	5
244	Hemodynamics after orthotopic liver transplantation: study of associated factors and long-term effects. Hepatology, 1995, 22, 458-465.	7.3	3
245	Systemic release of interleukin-10 during orthotopic liver transplantation. Hepatology, 1994, 20, 889-892.	7.3	72
246	Interleukin-6: an early marker of bacterial infection in decompensated cirrhosis. Journal of Hepatology, 1994, 20, 819-824.	3.7	78
247	Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology, 1994, 107, 505-516.	1.3	34
248	Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. Hepatology, 1993, 17, 175-178.	7.3	138
249	Herpesvirus Infection of the Respiratory Tract in Patients with Alcoholic Hepatitis. Alcoholism: Clinical and Experimental Research, 1992, 16, 979-981.	2.4	7
250	Fipexide-induced fulminant hepatitis. Journal of Hepatology, 1992, 15, 144-146.	3.7	23
251	Acute Liver Failure and Related Syndromes. , 0, , 1289-1312.		0
252	Management of Pretransplant Patients. , 0, , 1922-1930.		0